S. 43 · 119th Congress · Commerce

Skinny Labels, Big Savings Act

In committee702 words Introduced Jan 9, 2025 · Latest action Jan 9, 2025

How far it has goneStage 2 of 6
  1. IntroducedJan 9, 2025 Done
  2. CommitteeReferred to Judiciary Current stage
  3. Senate floorNot yet Not reached yet
  4. House floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

This bill provides a statutory safe harbor from patent infringement claims for generic or biosimilar manufacturers that seek or obtain approval for skinny labels of their drugs.

Under current law, the Food and Drug Administration (FDA) may approve generic and biosimilar drugs through a process known as skinny labeling, which allows a generic manufacturer to seek approval only for approved uses of the drug that are no longer protected by patents. However, in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., a court held that a generic manufacturer may sometimes be liable for patent infringement when it markets skinny label generics.

The bill specifically lists the following as actions that are not considered infringement of a method of use claim in a patent under the Federal Food, Drug, and Cosmetic Act:

• submitting or seeking approval of a skinny label for a generic or biosimilar drug;

• promoting or commercially marketing a drug with skinny labeling approved by the FDA; or

• describing a drug product approved by the FDA as a generic of, or therapeutically equivalent to, the branded drug.

The bill also applies the safe harbor to similar actions under the Public Health Service Act.

Congressional Research Service · summary of “Introduced in Senate” version · Jan 9, 2025

Who lobbies on it

10 organizations, more than 96% of Senate bills · 53 filings, incl. 3 naming only H.R. 6485 · Q1 2025–Q3 2026

These 10 organizations’ PACs gave $33K to 3 of the 4 members sponsoring or cosponsoring S. 43 in the 2025–26 election cycle.

See who got it, from which PACs, and how they compare to the rest of the Senate → Pro

One square per quarter since introduction, oldest left. Filled = named S. 43 or H.R. 6485 that quarter.

  1. Pharmaceutical Research and Manufacturers of America 7 of 7 quarters
    “Issues related to competition pracitces in the pharmaceutical marketplace. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.2658 - Medication Affordability and Patent Integrity Act (MAPIA). S.1095 - Stop STALLING Act. S.43 - Skinny Labels, Big Savings Act.”

    $26.6M lobbying spend in 2026 to date, all issuesQ3 2026 filing

  2. Association for Accessible Medicines 7 of 7 quarters
    “…H.R.6485/S.43: Skinny Labels, Big Savings Act. PTO rulemaking on inter partes review. H.R.5811: Restoring Americas Leadership in Innovation Act of 2025 (RALIA Act). Settled expectations discretionary denials.”

    $2.5M lobbying spend in 2026 to date, all issuesQ3 2026 filing · names both

  3. Novartis 6 of 7 quarters
    “S. 43: Skinny Labels, Big Savings Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 2276/HR. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) Biopharmaceutical innovation policy issues Bayh-Dole march-in…”

    $6.2M lobbying spend in 2026 to date, all issuesQ3 2026 filing

7 more organizations, every filingPROUpgrade

Organizations that named S. 43 or its companion H.R. 6485 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Reports naming only H.R. 6485 are included and tagged. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Members sponsoring the companion, H.R. 6485, are counted on that bill’s page, not here. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.

Actions

2 actions · newest first
  1. Jan 9, 2025Read twice and referred to the Committee on the Judiciary.
  2. Jan 9, 2025Introduced in Senate